Determining precisely how the ERBB and other kinase signaling pathways are dysregulated and co-opted by the EWS-WT1 chimeric transcription factor to drive tumor progression remains an open question and one that we can begin to investigate more effectively with these new DSRCT models. This evidence concerns the gene WT1 and neoplasm.